Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Connors

Showing results (131-140 of 977) with videos related to

Pageof 98
Sort By:
JAMA|March 22, 2022
Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current StatusJean M Connors, Paul M Ridker
Journal of Thrombosis and Thrombolysis|June 23, 2019
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosisNathan T Connell, Jean M Connors
Endocrinology|March 1, 1980
Feedback effectiveness of periodic versus constant triiodothyronine replacementJ M Connors, G A Hedge
Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology|August 1, 1982
Altitude-induced changes in plasma thyroxine, 3,5,3'-triiodothyronine, and thyrotropin in ratsJ M Connors, L G Martin
Endocrinology|June 1, 1981
Effect of continuous thyroxine administration on thyrotropin secretion in thyroidectomized ratsJ M Connors, G A Hedge
Future Cardiology|October 25, 2018
Betrixaban in the prevention of venous thromboembolism in medically ill patientsKatelyn W Sylvester, Jean M Connors
Blood Advances|November 27, 2019
Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancyHanny Al-Samkari, Jean M Connors
The Oncologist|December 10, 2013
New oral anticoagulants and the cancer patientNicholas J Short, Jean M Connors
Organic Letters|August 23, 2016
Regioselective Synthesis of Substituted Cyclopenta[l]phenanthrenesDavid M Connors, Nancy S Goroff
Hematology/Oncology Clinics of North America|October 3, 2007
New strategies for the treatment of early stages of Hodgkin's lymphomaDavid A Macdonald, Joseph M Connors
Pageof 98

Showing results (131-140 of 977) with videos related to

Sort By:
Pageof 98
JAMA|March 22, 2022
Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current StatusJean M Connors, Paul M Ridker
Journal of Thrombosis and Thrombolysis|June 23, 2019
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosisNathan T Connell, Jean M Connors
Endocrinology|March 1, 1980
Feedback effectiveness of periodic versus constant triiodothyronine replacementJ M Connors, G A Hedge
Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology|August 1, 1982
Altitude-induced changes in plasma thyroxine, 3,5,3'-triiodothyronine, and thyrotropin in ratsJ M Connors, L G Martin
Endocrinology|June 1, 1981
Effect of continuous thyroxine administration on thyrotropin secretion in thyroidectomized ratsJ M Connors, G A Hedge
Future Cardiology|October 25, 2018
Betrixaban in the prevention of venous thromboembolism in medically ill patientsKatelyn W Sylvester, Jean M Connors
Blood Advances|November 27, 2019
Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancyHanny Al-Samkari, Jean M Connors
The Oncologist|December 10, 2013
New oral anticoagulants and the cancer patientNicholas J Short, Jean M Connors
Organic Letters|August 23, 2016
Regioselective Synthesis of Substituted Cyclopenta[l]phenanthrenesDavid M Connors, Nancy S Goroff
Hematology/Oncology Clinics of North America|October 3, 2007
New strategies for the treatment of early stages of Hodgkin's lymphomaDavid A Macdonald, Joseph M Connors
Pageof 98